Pelthos Therapeutics Files 8-K for Reg FD Disclosure
Ticker: PTHS · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1919246
| Field | Detail |
|---|---|
| Company | Pelthos Therapeutics Inc. (PTHS) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, disclosure
TL;DR
Pelthos Therapeutics filed an 8-K for a Reg FD disclosure on 10/14/25.
AI Summary
Pelthos Therapeutics Inc. filed an 8-K on October 14, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself.
Why It Matters
This filing indicates Pelthos Therapeutics Inc. is making a public disclosure under Regulation FD, which ensures all investors receive the same material information simultaneously.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not contain information about significant financial changes, operational risks, or strategic shifts.
Key Players & Entities
- Pelthos Therapeutics Inc. (company) — Registrant
- October 14, 2025 (date) — Date of earliest event reported
- Regulation FD (regulation) — Type of disclosure
- Nevada (jurisdiction) — State of incorporation
- 4020 Stirrup Creek Drive, Suite 110 Durham, NC 27703 (address) — Principal executive office
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 14, 2025.
What is the state of incorporation for Pelthos Therapeutics Inc.?
Pelthos Therapeutics Inc. is incorporated in Nevada.
What is the principal executive office address of Pelthos Therapeutics Inc.?
The principal executive office is located at 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703.
What is the SIC code for Pelthos Therapeutics Inc.?
The Standard Industrial Classification (SIC) code is 2836 for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 896 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2025-10-14 07:46:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTHS The NYSE American LL
Filing Documents
- g084975_8k.htm (8-K) — 44KB
- g084975_ex99-1.htm (EX-99.1) — 35KB
- img001.jpg (GRAPHIC) — 453KB
- img002.jpg (GRAPHIC) — 1120KB
- img003.jpg (GRAPHIC) — 719KB
- img004.jpg (GRAPHIC) — 840KB
- img005.jpg (GRAPHIC) — 430KB
- img006.jpg (GRAPHIC) — 301KB
- img007.jpg (GRAPHIC) — 979KB
- img008.jpg (GRAPHIC) — 775KB
- img009.jpg (GRAPHIC) — 972KB
- img010.jpg (GRAPHIC) — 610KB
- img011.jpg (GRAPHIC) — 301KB
- img012.jpg (GRAPHIC) — 650KB
- img013.jpg (GRAPHIC) — 620KB
- img014.jpg (GRAPHIC) — 781KB
- img015.jpg (GRAPHIC) — 344KB
- img016.jpg (GRAPHIC) — 323KB
- img017.jpg (GRAPHIC) — 655KB
- img018.jpg (GRAPHIC) — 533KB
- img019.jpg (GRAPHIC) — 501KB
- img020.jpg (GRAPHIC) — 809KB
- img021.jpg (GRAPHIC) — 470KB
- 0001753926-25-001606.txt ( ) — 18419KB
- pths-20251014.xsd (EX-101.SCH) — 3KB
- pths-20251014_lab.xml (EX-101.LAB) — 33KB
- pths-20251014_pre.xml (EX-101.PRE) — 22KB
- g084975_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pelthos Therapeutics Inc. Date: October 14, 2025 By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Financial Officer